
|Articles|December 15, 2005
Glaucoma treatment focus of Novartis deal
Basel, Switzerland—Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.
Advertisement
Basel, Switzerland-Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.
The deal involves Y39983, a rho kinase inhibitor, under sub-license rights granted to Senju by Mitsubishi Pharma Corp.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmic innovation by the decades: The 2000s
2
The Residency Report: Social media and the modern ophthalmologist
3
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
4
AAO 2025: When and where to find all 18 named lectures
5